Long-Term Socioeconomic and Neurologic Outcome for Individuals with Childhood-Onset Multiple Sclerosis.
EQ-5D 5L
MSIS29
adolescent medicine
early onset
multiple sclerosis
natural history
paediatric onset
quality of life
socioeconomic
Journal
Children (Basel, Switzerland)
ISSN: 2227-9067
Titre abrégé: Children (Basel)
Pays: Switzerland
ID NLM: 101648936
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
received:
22
07
2024
revised:
15
08
2024
accepted:
20
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Most studies on the progression of childhood-onset multiple sclerosis (MS) involve relatively short follow-up periods, focusing primarily on neurological outcomes and disability progression. The influence of these and other factors on the health-related quality of life is not known. To gain a comprehensive understanding of early-onset MS, it is crucial to evaluate the effects of treatment and the disease on quality of life. This pilot project aimed to evaluate the feasibility of using an online survey tool for long-term follow-up data collection from patients with childhood-onset MS. An anonymized, monocentric, prospective survey was conducted on a convenience cohort of patients treated at a certified centre for neuromuscular diseases in childhood between 2007 and 2019. A total of 27 patients completed the survey. There were no mandatory items, therefore some patients chose not to answer all the questions in the questionnaire. Patients exhibited promising educational achievements, low neurological disease burden, and high resilience. However, anxiety, depression, and pain significantly impacted their perceived health status. This single-centre study has yielded new insights into childhood-onset MS. To enable more accurate comparisons across different centres and countries, it is essential to establish a minimum data set and questionnaire subset for patients with paediatric-onset MS transitioning into adulthood.
Identifiants
pubmed: 39201957
pii: children11081024
doi: 10.3390/children11081024
pmc: PMC11352636
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Merck (Germany)
ID : 2022-1
Références
Neurology. 2020 Mar 3;94(9):e932-e941
pubmed: 31732567
Med Care. 2001 Aug;39(8):800-12
pubmed: 11468499
Neurology. 2019 Jun 11;92(24):e2764-e2773
pubmed: 31092624
Ann Neurol. 2022 Apr;91(4):483-495
pubmed: 35150168
Eur J Paediatr Neurol. 2016 Jan;20(1):158-63
pubmed: 26387071
Cureus. 2022 May 19;14(5):e25146
pubmed: 35747044
Neurology. 2016 Aug 30;87(9 Suppl 2):S8-S11
pubmed: 27572866
Psychother Psychosom Med Psychol. 2006 Feb;56(2):42-8
pubmed: 16453241
Mult Scler. 2019 Mar;25(3):399-407
pubmed: 29363396
Mult Scler. 2016 Sep;22(10):1349-58
pubmed: 26564998
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Neurology. 2022 Apr 19;98(16):e1626-e1636
pubmed: 35437271
Brain. 2001 May;124(Pt 5):962-73
pubmed: 11335698
Mult Scler Relat Disord. 2020 May;40:101956
pubmed: 32007654
JAMA Neurol. 2021 Apr 1;78(4):478-482
pubmed: 33616605